1. Pulsed Field Ablation of Atrial Fibrillation: An Initial Australian Single-Centre Experience.
- Author
-
Lee XW, Freeman BM, Gunthorpe NG, Eagle LM, Webster MA, Betts JR, Denman RA, and Haqqani HM
- Subjects
- Humans, Australia epidemiology, Treatment Outcome, Recurrence, Atrial Fibrillation surgery, Pulmonary Veins surgery, Catheter Ablation methods
- Abstract
Background: Pulsed field ablation (PFA) is a newer ablation energy source with the potential to reduce complications and improve efficacy compared to conventional thermal atrial fibrillation (AF) ablation. This study aimed to present an initial single-centre Australian experience of PFA for AF ablation., Methods: Initial consecutive patients undergoing PFA for paroxysmal or persistent AF at a single centre were included. Baseline patient characteristics, procedural data and clinical outcomes were collected prospectively at the time of the procedure. Patients were followed up at 3 months and 6-monthly thereafter., Results: In total, 100 PFA procedures were performed in 97 patients under general anaesthesia. All pulmonary veins (403 of 403) were successfully isolated acutely. Median follow-up was 218 days (range, 16-343 days), and the Kaplan-Meier estimate for freedom from atrial arrhythmias at 180 days was 87% (95% confidence interval 79%-95%). Median procedure time was 74 minutes (range, 48-134 minutes). Median fluoroscopy dose-area product was 345 μGym
2 (interquartile range, 169-685 μGym2 ). Two (2%) pseudoaneurysm vascular access complications occurred. There were no cases of thromboembolic complications, stroke, phrenic nerve palsy, pulmonary vein stenosis, atrio-oesophageal fistula, or pericardial tamponade., Conclusions: Pulsed field ablation can be performed safely and efficiently, with encouraging efficacy in early follow-up. Further data and clinical trials will be required to assess the comparative utility of PFA in contemporary AF ablation practice., Competing Interests: Conflicts of Interest A/Prof. Haqqani has received speaking honoraria, consulting and proctoring fees from Boston Scientific, Medtronic. and Abbott. The remaining authors have no conflicts of interest to disclose., (Copyright © 2023 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF